Lactosylated gramicidin-based lipid nanoparticles (Lac-GLN) for targeted delivery of anti-miR-155 to hepatocellular carcinoma. - Wikidata - awgldk - TriplyDB

Lactosylated gramicidin-based lipid nanoparticles (Lac-GLN) for targeted delivery of anti-miR-155 to hepatocellular carcinoma.

Lactosylated gramicidin-based lipid nanoparticles (Lac-GLN) for targeted delivery of anti-miR-155 to hepatocellular carcinoma.

http://www.wikidata.org/entity/Q36901850

about

Role of Noncoding RNAs as Biomarker and Therapeutic Targets for Liver Fibrosis MicroRNA-155 and Its Role in Malignant Hematopoiesis miR-122 is a unique molecule with great potential in diagnosis, prognosis of liver disease, and therapy both as miRNA mimic and antimir Nanotechnology in cancer therapy MicroRNAs associated with HBV infection and HBV-related HCC.MicroRNA-155 deficiency enhances the recruitment and functions of myeloid-derived suppressor cells in tumor microenvironment and promotes solid tumor growth.MiRNA inhibition in tissue engineering and regenerative medicine.Targeted delivery of chemically modified anti-miR-221 to hepatocellular carcinoma with negatively charged liposomes.In Vivo Inhibition of miR-155 Promotes Recovery after Experimental Mouse Stroke MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice.Integrative transcriptome analysis identifies deregulated microRNA-transcription factor networks in lung adenocarcinoma.microRNA-155 deficiency impairs dendritic cell function in breast cancer.The multiple roles of microRNA-155 in oncogenesis.Active radar guides missile to its target: receptor-based targeted treatment of hepatocellular carcinoma by nanoparticulate systems.Strategies to antagonize miRNA functions in vitro and in vivo.Overcoming obstacles in microRNA delivery towards improved cancer therapy.miRNA nanotherapeutics for cancer.Nanomedicine in management of hepatocellular carcinoma: Challenges and opportunities.Variable asialoglycoprotein receptor 1 expression in liver disease: Implications for therapeutic intervention.AntihypoxamiR functionalized gramicidin lipid nanoparticles rescue against ischemic memory improving cutaneous wound healing.Enhanced antiproliferative activity of antibody-functionalized polymeric nanoparticles for targeted delivery of anti-miR-21 to HER2 positive gastric cancer.The new era of nanotechnology, an alternative to change cancer treatment.Evaluation of GalNAc-siRNA Conjugate Activity in Pre-clinical Animal Models with Reduced Asialoglycoprotein Receptor Expression.miR-155 in cancer drug resistance and as target for miRNA-based therapeutics.Nanotechnology based approaches for detection and delivery of microRNA in healthcare and crop protection.Silencing a Multifunctional microRNA Is Beneficial for Stroke Recovery.Targeted delivery of anti-miR-155 by functionalized mesoporous silica nanoparticles for colorectal cancer therapy.Colon Epithelial MicroRNA Network in Fatty Liver

P2860

Q26774309-1B0141DE-285E-43ED-A880-A2A8AA0B6B22 Q26777530-48AF634C-7E27-4E99-8180-AB26DAA94CE4 Q26991956-B44E6FFB-269E-4CEE-AFB7-06CB773DAD95 Q27023013-3187AD72-1BA9-4314-BCDA-315AB9BB7989 Q34284404-6230E62A-94F7-45AA-AAFC-BC39A34DA75D Q34899627-1367491F-63CE-48C8-9D67-5210B1B3858D Q35799937-6940EF43-3C37-424F-9B6C-135AB79173E5 Q35914942-19E46DF2-7484-4A9B-BD12-F64316DD8903 Q36038242-416C2C6D-1571-4133-BF8F-86B357108B97 Q36428863-8F747FBC-2445-4556-BB67-7E08ACA1A748 Q37301705-7F090CD1-195C-441F-AD43-C2C5F8644562 Q37477262-CEC000E1-2EF8-4031-A98E-0367D4E82EBB Q38145349-D45C70F7-6AC6-44F4-B731-7C9CB95BBB37 Q38271422-64C36685-B263-439F-BE18-87AEE6E5C317 Q38285749-839FF7DE-D54D-4924-8FE8-D29E3A0F1A77 Q38382967-0D23FB96-DB79-4DF9-AA48-C8C9A855EFFD Q38999082-A522256C-CFE2-44BD-8AFC-94DD223353B9 Q39012794-66D28396-AFB0-4820-9A88-12DFAAB92FC9 Q40482454-828574C2-5F7C-4F38-8D00-9DCB5E9DB310 Q41654073-F97F002E-B644-4271-B5B8-BD6F6118398E Q42366537-956B73BE-EB4C-4810-BC98-58BFCD83794D Q42370576-9DC517D8-2994-4688-91F7-3BA9E35A5B1C Q46291725-5D1EC74E-5682-4831-9EA8-5F4DA34281B6 Q49544999-8087C96C-C336-4AEC-925A-15FCC079208E Q52589516-6994F911-7D42-4A4F-831C-64D06DC53776 Q52661746-132FB0BB-A900-42F5-8930-36E21F7684D1 Q52726764-A54ECB32-9203-49A3-9609-E386E00576E6 Q57821607-B74C16A4-E4F4-4537-B553-1C84E8A6E9A3

P2860

Lactosylated gramicidin-based lipid nanoparticles (Lac-GLN) for targeted delivery of anti-miR-155 to hepatocellular carcinoma.

http://www.wikidata.org/entity/Q36901850

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Lactosylated gramicidin-based ...... 5 to hepatocellular carcinoma.

@en

type

label

Lactosylated gramicidin-based ...... 5 to hepatocellular carcinoma.

@en

prefLabel

Lactosylated gramicidin-based ...... 5 to hepatocellular carcinoma.

@en

P1433

Q36901850-D956A85F-A959-4CAC-BB18-3256328E0BBE

P1476

Q36901850-D79AF8FB-9578-405B-8A4B-61202DD1011D

P2093

Q36901850-2D74EA8C-8EEE-49C4-8B96-E85BB82FE668

Q36901850-63B87285-2CDF-4420-A3B0-5D92FE5A1EDA

Q36901850-80298A30-1953-4DDE-9A36-14D5F32D4867

Q36901850-BD14E5F6-2915-4CD4-BF0C-12045E4641AB

Q36901850-D92C9C1E-F5BE-456A-A900-081FBBA57363

Q36901850-E5EB5C74-1B8D-4989-9C86-34CC935B3704

Q36901850-FB6D4D53-525D-4D49-8223-9DF62BD4E537

P2860

Q36901850-004719B9-64E1-439E-8FAC-76A736FDFC90

Q36901850-00B201B2-CC0F-402D-B500-27A1CC1B9A22

Q36901850-0552EC1D-3021-4519-9832-E7254C679FCE

Q36901850-0566707B-48DF-4FC4-835A-A18C87CE3648

Q36901850-074E5DF4-F26A-4FA6-A1C5-56A0395A0EFE

Q36901850-14242B82-278B-4B8F-8BC2-A944703BFC25

Q36901850-1E6712BA-82D8-4005-A8A8-32ECC2B5B29D

Q36901850-2109FA8F-7BAB-4094-848F-C48B3F64FFA2

Q36901850-252DCC64-CA13-421C-BF8D-2EC7BE90699B

Q36901850-2DBC5E7D-A008-4CB6-B551-F31A18AA59D5

P304

Q36901850-365F3A55-F831-4808-BEC9-110173EF57C5

P31

Q36901850-87D02FA1-D1BE-4354-98A3-C4C342FA5C03

P356

Q36901850-F34DC752-06B0-4876-9179-C269C2C467FB

P407

Q36901850-D6503357-22E6-4927-AE16-77BC276AB0F8

P433

Q36901850-78BD0C61-16BB-4611-97B3-C7946C1DBD98

P478

Q36901850-4D2C83F9-A48B-4DE1-9710-0192085DC585

P577

Q36901850-2836820B-2D3B-48B6-93FC-9C8E2AB0AE6F

P698

Q36901850-981F84C2-07BA-4A3A-831B-2A4425E1891B

P921

Q36901850-DD58EE0F-9FE5-47EE-822F-04076AA0CC0B

P932

Q36901850-723CC63A-0FAC-42A3-BE2B-8AD65C1DA83F

P356

J.JCONREL.2013.03.020

P1433

Journal of Controlled Release

P1476

Lactosylated gramicidin-based ...... 5 to hepatocellular carcinoma.

@en

P2093

Bo Wang

http://www.w3.org/2001/XMLSchema#string

Bryant C Yung

http://www.w3.org/2001/XMLSchema#string

Kalpana Ghoshal

http://www.w3.org/2001/XMLSchema#string

Ly J Lee

http://www.w3.org/2001/XMLSchema#string

Mengzi Zhang

http://www.w3.org/2001/XMLSchema#string

Robert J Lee

http://www.w3.org/2001/XMLSchema#string

Xiaoju Zhou

http://www.w3.org/2001/XMLSchema#string

P2860

A microRNA expression signature of human solid tumors defines cancer gene targets

Accumulation of miR-155 and BIC RNA in human B cell lymphomas

miRiad roles for the miR-17-92 cluster in development and disease

Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice

A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure

MicroRNA-155 is induced during the macrophage inflammatory response

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

A microRNA polycistron as a potential human oncogene

Novel approaches for gene-specific interference via manipulating actions of microRNAs: examination on the pacemaker channel genes HCN2 and HCN4

Lipid bilayer regulation of membrane protein function: gramicidin channels as molecular force probes

P304

251-261

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JCONREL.2013.03.020

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

168

http://www.w3.org/2001/XMLSchema#string

P577

2013-04-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23567045

http://www.w3.org/2001/XMLSchema#string

P921

P932

3672318

http://www.w3.org/2001/XMLSchema#string